myNEO Therapeutics to focus on building proprietary product pipeline based on a novel class of shared therapeutic cancer targets derived from the dark genome named “camyotopes” Lead product CAMYO-01 incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccineCAMYO-01 is advancing towards clinical development for the treatment of colorectal cancer GHENT, Belgium – October 25th 2023. myNEO, a biotech company focused on exploiting “dark genome” targets to devel
myNEO Therapeutics to focus on building proprietary product pipeline based on a novel class of shared therapeutic cancer targets derived from the dark.
Issuer: CureVac / Key word(s): Alliance25.05.2022 / 13:00 The issuer is solely responsible for the content of this announcement.CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development CureVac is broadening its foundation in oncology, leveraging recent progress with it.
CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backboneThe partnership combines CureVac's mRNA technology with myNEO's platform for the discovery